The Cardiac Arrhythmia Network of Canada (CANet) is a pan-Canadian organization. Our members are patients, caregivers, investigators, and healthcare providers. We partner with academic institutions, globally recognized industries, not-for-profit organizations, and federal and provincial government agencies.
These unique relationships combine patient engagement, arrhythmia research, digital health advancements, innovation, and commercialization activities to develop and distribute cutting-edge scientific discoveries and technologies to improve cardiac arrhythmia patients’ lives and create business opportunities.
Scroll down to see highlights, learn about our impacts, and discover more about our network initiatives.
CANet Patient Partner Hugh Winsor has participated on both CANet’s Research Management Committee and the International Expert Advisory Committee (where the scoring of most research proposals starts.)
In these roles, he reviews investigators’ applications for project funding (as well as following up on how the funded investigators are proceeding on their projects.)
“A patient brings to this process his or her own experience of the various procedures and treatment they have received, and how it impacted the rest of their lives. They have an appreciation of their own priorities as well as the likely priorities of other patients with similar experiences,” he says.
Expert Knowledge Exchange
Building for the Future
November 17-18, 2022
Join CANet at our upcoming event dedicated to students, allied health professionals, learners and patient partners.
With our vision of patient-driven care for all Canadians, along with ground-breaking CANet-funded research, we continue to assemble innovative digital health technologies.
Apart from VIRTUES, our patient-centred virtual care platform, several of our successful research programs have a global impact. View some of our recent project highlights below. To learn more about all impacts made by our Network, click here.
One of the first programs funded by CANet and the largest clinical trial of its kind, EARLY-AF, found that there was a significantly lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation than with antiarrhythmic drug therapy. The results of this study have recently been published in the New England Journal of Medicine with numerous invited presentations at national/international conferences.
CANet reported the first-ever test flights of drone-delivered AEDs in Canada in simulated mock 9-1-1 responses. The chances of surviving a cardiac arrest decrease by 7 to 10 % for every minute over 10 minutes. This novel, innovative delivery system has significantly reduced the time to AED arrival at the scene of a cardiac arrest from 20 minutes to 10.6 minutes in rural regions.
CANet-funded C-SCAN successfully advocated for a mandatory AED registry in Ontario and helped draft legislation to create a mandatory Provincial AED registry, Bill 141 Defibrillator Registration and Public Access Act, 2020. This legislation received royal assent in June 2020.